1. Search Result
Search Result
Results for "

( )-JQ1 PA

" in MedChemExpress (MCE) Product Catalog:

152

Inhibitors & Agonists

2

Fluorescent Dye

3

Biochemical Assay Reagents

16

Peptides

3

Inhibitory Antibodies

15

Natural
Products

23

Recombinant Proteins

24

Isotope-Labeled Compounds

6

Antibodies

3

Click Chemistry

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-112789
    (+)-JQ1 PA
    1 Publications Verification

    Epigenetic Reader Domain Cancer
    (+)-JQ1 PA is a derivative of the Bromodomain and extra-terminal (BET) inhibitor JQ1, with an IC50 of 10.4 nM. (+)-JQ1 PA is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    (+)-<em>JQ1</em> <em>PA</em>
  • HY-13030
    (+)-JQ-1
    Maximum Cited Publications
    199 Publications Verification

    JQ1

    Epigenetic Reader Domain Autophagy Ligands for Target Protein for PROTAC Cancer
    (+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)) [1]. (+)-JQ-1 also activates autophagy .
    (+)-<em>JQ-1</em>
  • HY-78695
    JQ-1 (carboxylic acid)
    3 Publications Verification

    Epigenetic Reader Domain PD-1/PD-L1 Cancer
    JQ-1 carboxylic acid, a (+)-JQ-1 (HY-13030) derivative, is a potent BET bromodomain inhibitor. JQ-1 carboxylic acid can be used to synthesize PROTAC, which can target the degradation of BRD4.
    <em>JQ-1</em> (carboxylic acid)
  • HY-148864

    Epigenetic Reader Domain Cancer
    JQ1-TCO is the double bond E configuration of JQ1-TCO (HY-148864A). JQ1-TCO (JQ1-trans-cyclooctene) is a derivative of JQ1 (HY-13030), an inhibitor of BET. JQ1-TCO is suitable for click chemistry and can be used as molecular probes in vitro and in vivo [1] .
    <em>JQ1</em>-TCO
  • HY-161125

    Others Others
    (+)-JQ1-OH is the major metabolite of (+)-JQ1(HY-13030). (+)-JQ-1 (JQ1) is a potent, specific, and reversible BET bromodomain inhibitor, with IC50s of 77 and 33 nM for the first and second bromodomain (BRD4(1/2)). (+)-JQ-1 also activates autophagy [1].
    (+)-<em>JQ1</em>-OH
  • HY-145667

    Biotin-JQ1

    Epigenetic Reader Domain Cancer
    Biotinylated-JQ1 (Biotin-JQ1) is a biotinylated derivative of JQ1 with high affinity for the bromodomain of BRD4. Biotinylated-JQ1 inhibits MM1.S multiple myeloma cells proliferation with the EC50 of 0.4 μM [1].
    Biotinylated-<em>JQ1</em>
  • HY-13030A
    (R)-(-)-JQ1 Enantiomer
    5+ Cited Publications

    Epigenetic Reader Domain Cancer
    (R)-(-)-JQ1 Enantiomer is the stereoisomer of (+)-JQ1. (+)-JQ1 potently decreases expression of both BRD4 target genes, whereas (R)-(-)-JQ1 Enantiomer has no effect.
    (R)-(-)-<em>JQ1</em> Enantiomer
  • HY-148864A

    Epigenetic Reader Domain Cancer
    JQ1-TCO (JQ1-trans-cyclooctene) is a derivative of JQ1 (HY-13030), an inhibitor of BET. JQ1-TCO is suitable for click chemistry and can be used as molecular probes in vitro and in vivo [1] .
    (Z)-<em>JQ1</em>-TCO
  • HY-131633A

    Epigenetic Reader Domain Cancer
    (+)-JQ-1-aldehyde is the aldehyde form of (+)-JQ1. (+)-JQ-1-aldehyde can be uesd as a precursor to synthesize PROTACs, which targets BET bromodomains [1].
    (+)-<em>JQ-1</em>-aldehyde
  • HY-129917
    KB02-JQ1
    2 Publications Verification

    PROTACs Epigenetic Reader Domain Cancer
    KB02-JQ1 is a highly selective and PROTAC-based BRD4 degrader (molecular glue), but does not degrade BRD2 or BRD3. KB02-JQ1 promotes BRD4 degradation by covalently modifying DCAF16 (E3 ligase) and can improve the durability of protein degradation in biological systems. JQ1 binds ubiquitin E3 ligase ligand KB02 via a linker to form KB02-JQ1 [1].
    KB02-<em>JQ1</em>
  • HY-156214

    AP1867-PEG2-JQ1; AP-PEG2-JQ1

    Others Others
    NICE-01 (AP1867-PEG2-JQ1; AP-PEG2-JQ1) is a bifunctional compound that bind to proteins in separate cellular compartments that can induce nuclear import of cytosolic cargoes, using nuclear-localized bromodomain-containing protein 4 (BRD4) as a “carrier” for co-import and nuclear trapping of cytosolic proteins [1].
    NICE-01
  • HY-147046

    Epigenetic Reader Domain Cancer
    ET-JQ1-OH is an allele-specific BET inhibitor [1].
    ET-<em>JQ1</em>-OH
  • HY-130256

    PROTACs Epigenetic Reader Domain Cancer
    β-NF-JQ1 is a PROTAC that recruits Aryl Hydrocarbon Receptor E3 ligase to target proteins. β-NF-JQ1 is directed against bromodomain-containing (BRD) proteins using β-NF as an AhR ligand, induces the interaction of AhR and BRD proteins, and displays effective anticancer activity that correlated with protein knockdown activity [1].
    β-NF-<em>JQ1</em>
  • HY-153574

    PArg-JQ1

    PROTACs Epigenetic Reader Domain Infection
    BI01826025 (pArg-JQ1) is a bromodomain1 of BRDT (BRDTBD1) PROTAC degrader. BI01826025 can be used for testing the regulatory effect of ClpC2 on the ClpC1P1P2 protease [1].
    BI01826025
  • HY-153573

    dCym-JQ1

    PROTACs Epigenetic Reader Domain Infection
    SRG-II-19F (dCym-JQ1) is a bromodomain1 of BRDT (BRDTBD1) PROTAC degrader. SRG-II-19F can be used for testing the regulatory effect of ClpC2 on the ClpC1P1P2 protease [1].
    SRG-II-19F
  • HY-112544
    IK1 inhibitor PA-6
    1 Publications Verification

    PA-6

    Potassium Channel Cardiovascular Disease
    IK1 inhibitor PA-6 (PA-6), a pentamidine analogue, is a selective and potent IK1 (KIR2.x ion-channel-carried inward rectifier current) inhibitor, with IC50 values of 12-15 nM for human and mouse KIR2.x currents. IK1 inhibitor PA-6 (PA-6) elevates KIR2.1 protein expression and induces intracellular KIR2.1 accumulation. IK1 inhibitor PA-6 (PA-6) has the potential to treat atrial fibrillation and arrhythmia [1] .
    IK<em>1</em> inhibitor <em>PA</em>-6
  • HY-111823

    VHL ligand 6

    Ligands for E3 Ligase Cancer
    VH032 thiol (VHL ligand 6) is a VHL ligand, which binds to pan-BET inhibitor JQ1 via a linker to form PROTAC [1].
    VH032 thiol
  • HY-129421

    PACAP Receptor Neurological Disease Inflammation/Immunology
    PA-9 is a pituitary adenylate cyclase-activating polypeptide (PACAP) type I (PAC1) receptor antagonist. PA-9 dose dependently inhibits PACAP-induced cAMP elevation with an IC50 of 5.6 nM. PA-9 can be used for the research of neuropathic and/or inflammatory pain [1].
    <em>PA</em>-9
  • HY-10844
    Pretomanid
    3 Publications Verification

    PA-824; (S)-PA 824

    Bacterial Antibiotic Infection Cancer
    Pretomanid (PA-824) is an antibiotic used for the research of multi-drug-resistant tuberculosis affecting the lungs. Pretomanid exhibits a sub-micromolar MIC against M. tuberculosis (MTB). The MIC values of PA-824 against a panel of MTB pan-sensitive and Rifampin mono-resistant clinical isolates range from 0.015 to 0.25 μg/mL.
    Pretomanid
  • HY-133529

    PACAP Receptor Neurological Disease Inflammation/Immunology
    PA-8 is a potent, selective and orally active PACAP type I (PAC1) receptor antagonist. PA-8 inhibits the phosphorylation of CREB induced by PACAP in PAC1-, but not VPAC1- or VPAC2-receptor. PA-8 also inhibits PACAP-induced cAMP elevation with an IC50 of 2 nM [1] .
    <em>PA</em>-8
  • HY-100696

    PNZ5 is a potent and isoxazole-based pan-BET inhibitor with high selectivity and potency similar to the well-established (+)-JQ1, with a KD of 5.43 nM for BRD4(1) [1].
    PNZ5
  • HY-103495

    GABA Receptor Neurological Disease
    17-PA is a selective antagonist of neurosteroid potentiation and direct gating of GABA A receptors [1].
    17-<em>PA</em>
  • HY-144767

    Bacterial Infection
    PA3552-IN-1 (compound 15) is an antibiotic adjuvant that restores sensitivity of MDR P. aeruginosa DK2 strain to Polymyxin B. PA3552-IN-1 can reduce PA3552 expression [1].
    <em>PA</em>3552-IN-<em>1</em>
  • HY-101838
    dBET1
    10+ Cited Publications

    PROTACs Epigenetic Reader Domain Cancer
    dBET1 is a PROTAC connected by ligands for Cereblon and BRD4 with an EC50 of 430 nM. dBET1 is a PROTAC that composes of (+)-JQ1 (HY-13030) linked to NSC 527179 (HY-14658) with a linker [1].
    dBET<em>1</em>
  • HY-P5981

    Biochemical Assay Reagents Others
    Chromozym t-PA can be used for determination of t-PA (tissue plasminogen activator) concentration [1]
    Chromozym t-<em>PA</em>
  • HY-131385

    Ligands for E3 Ligase Cancer
    KB02-COOH is a fragment of synthesis of ubiquitin E3 ligase ligand KB02. KB02 can be used in the synthesis of PROTAC, such as KB02-JQ1 (HY-129917) and KB02-SLF (HY-129610) [1].
    KB02-COOH
  • HY-155684

    PROTACs VEGFR PDGFR Ephrin Receptor Cancer
    SA-PA is an intracellular self-assembled PROTAC based on azide and alkyne. SA-PA is able to selectively degrade VEGFR-2, PDGFR-β and EphB4 proteins in U87 cells. SA-PA can be converted to PROTAC in situ by click reaction with the help of endogenous copper in tumor tissues [1].
    SA-<em>PA</em>
  • HY-149594

    Others Metabolic Disease
    CL-Pa is a chemiluminescent probe suitable for detection of urinary Vanin-1. CL-Pa can be used to detect drug-induced acute kidney injury (AKI) through urinalysis [1].
    CL-<em>Pa</em>
  • HY-111875

    SNIPERs Epigenetic Reader Domain Cancer
    SNIPER(BRD)-1, consists of an IAP antagonist LCL-161 derivative and a BET inhibitor, (+)-JQ-1, connected by a linker. SNIPER(BRD)-1 induces the degradation of BRD4 via the ubiquitin-proteasome pathway. SNIPER(BRD)-1 also degrades cIAP1 , cIAP2 and XIAP with IC50s of 6.8 nM, 17 nM, and 49nM, respectively [1].
    SNIPER(BRD)-<em>1</em>
  • HY-160528

    Epigenetic Reader Domain Molecular Glues Cancer
    IBG3 is a dual-JQ1-containing BET degrader that targets protein degradation via intramolecular bivalent glues. IBG3 is a BRD2 and BRD4 bifunctional degrader with DC50 values of 8.6 pM and 6.7 pM, respectively [1].
    IBG3
  • HY-133535

    PA-JF646-NHS

    Fluorescent Dye Others
    PA Janelia Fluor® 646, SE (PA-JF646-NHS), a photoactivatable fluorescent dye, is an NHS ester for coupling to primary amine groups. PA-JF646-NHS is non-fluorescent until activated at 365 nm. NHS ester can be converted to relevant substrate for use in self-labeling tag systems, e.g.HaloTag ® and SNAP-tag ®. PA-JF646-NHS is used for single molecule tracking and super resolution microscopy in live cells, specifically live cell sptPALM and fixed cell PALM. (λExcitation/emission~650/664 nm). Janelia Fluor® products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
    <em>PA</em> Janelia Fluor® 646, SE
  • HY-146896S

    Isotope-Labeled Compounds Others
    16:0-18:1 PA-d31 (sodium) is deuterium labeled 16:0-18:1 PA (sodium).
    16:0-18:<em>1</em> <em>PA</em>-d31 sodium
  • HY-W007545

    PROTAC Linker 35

    PROTAC Linkers Cancer
    NH2-PEG3 (PROTAC Linker 35) is a PROTAC linker, which belongs to a polyethylene glycol (PEG) linker. NH2-PEG3 (PROTAC Linker 35) can be used in the synthesis of the PROTAC (β-NF-JQ1) [1].
    NH2-PEG3
  • HY-133534

    Others Others
    PA-Nic TFA is a photoactivatable nicotine, whcih can be photolyzed with ~405 nm laser flashes to efficiently release nicotine [1].
    <em>PA</em>-Nic TFA
  • HY-130842

    β-NF-CH2-Br

    Ligands for E3 Ligase Cancer
    β-Naphthoflavone-CH2-Br (β-NF-CH2-Br) is an arylhydrocarbon receptor (AhR) ligand. β-Naphthoflavone-CH2-Br can be used to synthesize the PROTAC β-NF-JQ1(HY-130256) [1].
    β-Naphthoflavone-CH2-Br
  • HY-108522
    PA452
    1 Publications Verification

    RAR/RXR Metabolic Disease
    PA452, retinoic X receptor (RXR) specific antagonist, inhibits the effect of Retinoic acid (RA) on Th1/Th2 development [1].
    <em>PA</em>452
  • HY-P1580

    Influenza Virus Infection
    PA (224-233), Influenza is a 10-aa peptide, a fragment of polymerase 2 protein in influenza A virus.
    <em>PA</em> (224-233), Influenza
  • HY-N0842
    Bevirimat
    1 Publications Verification

    PA-457; MPC-4326; YK FH312

    HIV Infection
    Bevirimat (PA-457; MPC-4326; YK FH312) is an anti-HIV agent derived from a betulinic acid-like compound; is believed to inhibit HIV by a novel mechanism, so-called maturation inhibition.
    Bevirimat
  • HY-133536

    PA-JF549-NHS

    Fluorescent Dye Others
    PA Janelia Fluor 549, SE (PA-JF549-NHS) is a bright photoactivatable fluorophore of JF549,SE (JF549,NHS). JF549,SE (JF549,NHS) is a fluorescent dye with the absorption maximum (λab (max)) of 549 nm and emission maximum (λem (max)) of 571 nm [1] . Janelia Fluor products are licensed under U.S. Pat. Nos. 9,933,417, 10,018,624 and 10,161,932 and other patents from Howard Hughes Medical Institute.
    <em>PA</em> Janelia Fluor® 549, SE
  • HY-129968

    PROTAC Linkers Cancer
    AM-Imidazole-PA-Boc is an alkyl chain-based PROTAC linker can be used in the synthesis of PROTAC IRAK4 degrader-1 (HY-129966) [1].
    AM-Imidazole-<em>PA</em>-Boc
  • HY-132141

    5-ProPArgylamino-dUTP

    DNA/RNA Synthesis Others
    5-PA-dUTP (5-Propargylamino-dUTP) is a C5-modified nucleotide and can be incorporated into DNA nanoparticles (DNPs) for photosensitizer delivery [1]. 5-PA-dUTP is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    5-<em>PA</em>-dUTP
  • HY-114407

    PROTACs Epigenetic Reader Domain Cancer
    TD-428 is a PROTAC connected by ligands for Cereblon and BRD4. TD-428 is a highly specific BRD4 degrader with a DC50 of 0.32 nM [1]. TD-428 is a BET PROTAC, which comprises TD-106 (a CRBN ligand) linked to JQ1 (a BET inhibitor). TD-428 efficiently induce BET protein degradation [1].
    TD-428
  • HY-RS09947

    Small Interfering RNA (siRNA) Others

    PA2G4 Human Pre-designed siRNA Set A contains three designed siRNAs for PA2G4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

    PA2G4 Human Pre-designed siRNA Set A
    PA2G4 Human Pre-designed siRNA Set A
  • HY-19541A

    Epigenetic Reader Domain Cancer
    I-CBP112 hydrochloride is a selective inhibitor of CBP/P300 that directly binds their bromodomains (Kds = 142 and 625 nM, respectively). I-CBP112 significantly reduces the leukemia-initiating potential of MLL-AF9(+) acute myeloid leukemia cells in a dose-dependent manner in vitro and in vivo. I-CBP112 increases the cytotoxic activity of BET bromodomain inhibitor JQ1 as well as doxorubicin [1].
    I-CBP112 hydrochloride
  • HY-157045

    ATP Synthase Infection
    ATP Synthesis-IN-1 (Compound 4), quinoline derivative, is a potent inhibitor of PA ATP synthesis activity. ATP Synthesis-IN-1 has PA ATP synthesis inhibition with IC50 value of 11.1μg/mL. ATP Synthesis-IN-1 also has antibacterial activity. ATP Synthesis-IN-1 can be used for the research of drug-resistant PA infection [1].
    ATP Synthesis-IN-<em>1</em>
  • HY-133590

    Others Cancer
    Heliotrine N-oxide is the corresponding PA (pyrrolizidine alkaloid) N-oxide of Heliotrine (HY-126128). Heliotrine N-oxide leads to the formation of pyrrolic DNA adducts and potential initiation of PA-induced liver tumors in vivo [1].
    Heliotrine N-oxide
  • HY-41919

    mDPR(boc); (S)-MALEOYL-DPR(BOC)-OH·DCHA

    Mal-L-PA-NH-Boc is a noncleavable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
    Mal-L-<em>PA</em>-NH-Boc
  • HY-130269

    β-NF-CH2-OH

    Ligands for E3 Ligase Cancer
    β-Naphthoflavone-CH2-OH (β-NF-CH2-OH) is a ligand for arylhydrocarbon receptor (AhR) E3 ligase. β-Naphthoflavone-CH2-OH can be connected to the ligand for protein by a linker to form PROTACs or SNIPERs (e.g., β-naphthoflavone-JQ1) that recruit the AhR E3 ligase complex by incorporating AhR ligands into chimeric molecules. PROTACs are inducers of ubiquitination-mediated degradation of cancer-promoting proteins [1].
    β-Naphthoflavone-CH2-OH
  • HY-111915

    18:1 PA

    Liposome Others
    1,2-Dioleoyl-sn-glycero-3-phosphate sodium salt (18:1 PA) is an anionic lipid that can be used to prepare liposomes, micelles and artificial membranes [1] .
    <em>1</em>,2-Dioleoyl-sn-glycero-3-phosphate, sodium salt
  • HY-W013549

    6-APA

    Bacterial Infection
    6-Aminopenicillanic acid (6-APA) is an important precursor for the synthesis of -lactam antibiotics. 6-Aminopenicillanic acid is the main product of Penicillin G (PenG) hydrolyzed by penicillin acylase (PA) [1].
    6-Aminopenicillanic acid

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: